Core Laboratories Inc. /DE/

During our fiscal quarter ended December 31, 2025, no director or officer of the Company adopted, modified orterminatedany “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement” within the meaning of Item 408(a) of Regulation S-K.

NYSE Notification

On March 18, 2026, the Company received a notice of noncompliance (the “NYSE Notice”) from the New York Stock Exchange (“NYSE”) noting that the Company is not in compliance with Section 802.01E of the NYSE Listed Company Manual due to the delayed filing of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (the “Form 10-K”).

As previously reported in the Company’s Notification of Late Filing on Form 12b-25 filed with the SEC on March 3, 2026 (the “Form 12b-25”), the Company was unable to file the Form 10-K within the prescribed period because additional time, resources and effort were required to complete work related to its financial reporting and closing procedures, specifically in connection with income tax accounting matters across various international jurisdictions. Subsequent to filing the Form 12b-25, the Company continued to dedicate significant resources to the accounting analysis and completion of those procedures but was unable to file the Form 10-K by March 17, 2026, the end of the 15-day extension period provided by the Form 12b-25.

The NYSE Notice has no immediate effect on the listing of the Company’s common stock on the NYSE. The NYSE Notice informed the Company that, under NYSE rules, the Company has six months from March 18, 2026 to regain compliance with the NYSE listing standards by filing the Form 10-K with the SEC. If the Company fails to file the Form 10-K within the six-month period, the NYSE may grant, in its sole discretion, an extension of up to six additional months for the Company to regain compliance, depending on the specific circumstances. The NYSE Notice also notes that the NYSE may nevertheless commence delisting proceedings at any time if it deems that the circumstances warrant.

As a result of filing this Form 10-K on March 20, 2026, the Company believes it has fully regained compliance with NYSE listing standards.

Correction of Information in Current Report on Form 8-K/A filed on March 17, 2026

On March 17, 2026, the Company filed a Form 8-K/A (the “Amended Report”) with the Securities and Exchange Commission, which amended and supplemented the Company’s Current Report on Form 8-K filed on February 4, 2026 (the “Original Form 8-K”). The Amended Report was filed to correct certain financial information contained in Exhibit 99.1 to the Original Form 8-K. The sole purpose of this disclosure is to correct certain financial information contained in the Amended Report.

In completing the reconciliation and corresponding controls for preparation of the financial statements to be included in the Annual Report on Form 10-K for the year ended December 31, 2025, the Company determined that the adjustment to estimated income tax expense for the quarter and year ended December 31, 2025 as reported in the Amended Report was overstated by $2.0 million. The final income tax expense adjustments have been recorded by the Company, which resulted in decreasing deferred income tax expense by $2.0 million, decreasing deferred tax liabilities by $2.0 million, and increasing net income by $2.0 million for the year-ended December 31, 2025.

The adjustment to income tax expense did not have any impact on, or result in any change to, consolidated revenue, operating income, income before tax, or cash from operations as presented in the Original Form 8-K.